CAS Name: (5a,17b)-17-Methyl-2’H-androst-2-eno[3,2-c]pyrazol-17-o
Stanozolol is a17-alpha-alkylated anabolic steroid with good oral bioavailability. While stanazolol’s androgenic activity index of stanozolol is nearly the same as testosterone, its myotrophic activity is much higher at 2.0–3.7. Stanozolol does not aromatize and does not cause water retention.
Stanozolol has been used for weight loss management in HIV patients with chronic obstructive pulmonary disease and has showed significant improvement in weight, body mass index, LBM, and muscle size. Stanozolol has been shown in vitro to significantly enhance collagen synthesis. A positive effect of stanazolol on wound healing in patients with non-healing wounds has also been demonstrated. Clinical studies show that the treatment with stanozolol during the induction phase of chemotherapy results in a positive effect on the duration of cancer-free remission.
|each tablet contains:|
|Benzyl Alcohol||BP||0.9% v/v|
|Carmellose Sodium||BP||0.1% w/v|
|Water for Injections||BP||q.s.|
Packing: 10 * 1 miL Glass Vial
Dosage and administration
Effective adult dose (men): 300-400mg per week by intramuscular injection
As with all 17-alpha-alkylated oral steroids, stanazolol has some liver toxicity especially with increases in daily dose and therapy duration. But long-term study of patients treated with stanozolol and followed for 15–47 months did not show any harmful effect on the liver.
Stanozolol has negative effect on cholesterol profile rise in LDL and decrease in HDL. 6 weeks oral stanozolol at a dose of 6 mg/day resulted in a more adverse lipid profile than an IM injection of of 200 mg/wk testosterone. During stanozolol treatment, HDL level can be decrease as much as 30-40%.
Low level of HDL, pregnancy, breast feeding.